Microsoft word - biography-publications of rishat abbas-borhan-aug 2013.doc

Brief Biography and Publication of Richat Abbas-Borhan (Rishat Abbas), PhD

Dr. Richat Abbas-Borhan (Rishat Abbas) is a Director and Clinical Pharmacology Lead at Pfizer. He
received his PhD in Pharmaceutical Sciences (with focus on pharmacokinetics/pharmacodynamics) from
the Ohio State University, USA, in 1994. Dr. Abbas-borhan worked on research projects in government
research laboratory, Bio-Tech and pharmaceutical research/development (R&D) in the United States. He
conducted research on development of new medicines from preclinical to clinical in positions of
increasing responsibility, and contributed to the research/development of new cardiovascular
(PLETAL), central nervous system (Abilify), diabetes (Oral Insulin – in R&D) and anti-cancer drugs
(Tarceva and Bosulif). He has authored/co-authored more than 130 peer reviewed publications,
presentations, patents and book charpters in the area of drug research and development. Dr. Abbas-
Borhan received a number of prestigious awards, including Science and Technology Achievement Award
from the U.S. Department of Defense (1996); Scientific Achievement Award from the U.S. Department of
Air Force (1996); Best Paper Award from the Society of Toxicology (1999); Best Abstract Award from
the Diabetes Technologies Meeting (2001); Exceptional Innovation/Achievement Award for outstanding
contribution to research projects (cardiovascular safety evaluation of a neratinib, 2009); Milestone
Recognition Award for outstanding contribution leading to an important research decision point for a new
anti-cancer drug (2009). Since 2006, he has been featured in several Editions of Who’s Who in America
and Who's Who in the World. He is a member of the American Society of Clinical Pharmacology &
Therapeutics, American College of Clinical Pharmacology, and American Association of Pharmaceutical
Scientists.
(E-mail: [email protected])
Dr. Rishat Abbas Borhanning Qisqiche Terjimehali
Doktur Rishat Abbas Borhan (Richat Abbas) nowette Amerikining tibbi dora tetqiqat we tereqqi
qildurush sayiside xelgharada yitekchi orunda turidighan birleshme idarisi – Pfizer de rak ve bashqa
kiselliri dora tetqiqat tarmighining bash yitekchi (Lead Clinical Pharmacologist/Principle Investigator)
tetqiqatchisi we Clinical Pharmacology tarmighining directori bolup xizmet qilmaqta (2004-yilidin
hazirqiche).
Rishat Abbas Borhan 1989- yili Urumchidin Amerikigha oqushqa kilip, 1994- yili Ohio Shitatliq
Uniwersititida (The Ohio State University, Columbus, OH, USA) Tibbi Dora tetqiqat Ilmi boyiche
Dokturluq Unwanigha erishken. 1994- yilidin 1996-yilighiche, Rishat Abbas Borhan Amerika Dolet
Mudapie Ministirligi Hawa Armiyisining tetqiqat tejirbihanisida (Wright-Patterson Air Force Base,
Dayton, OH, USA) Doktur Ashdi Tetqiqati bilen shughullan’ghan. 1994- yilidin hazirghiqe bolghan
Amerikadiki tibbi dora tetqiqat xizmet hayatida, Rishat Abbas Borhan Amerika doletlik tetqiqat
tejirbixanilirida, Xelq'araliq Tibbi Dora tetqiqat idariliride yingi dorilarni tetqiq we tereqqi qildurush
sahiyeside zor unumluk tetqiqat xizmetliride bolghan we yuquri derijilik tetqiqat netijilerge irishken.
Rishat Abbas Borhan yingi dorilarni tetqiq qilish, istimal qilish we tereqqi qildurush hemde ularni
Kilinikiliq tetqiqat tejirbidin otkuzush jehetliride, dawamliq muhim mesuliyetlerni oz ustige ilip, alahide
netijilerge irishti. Bularning ichide: Rak Kiselligige shipa bolidighan dora - Tarceva (Erlotinib) we
Bosulif (Bosutinib), yurek-qan tomur kisellirige shipa bolidighan yingi dorilar- PLETAL, nerwe
kiselirige dewa - Abilify, hemde Diabetes kisellirige shipa bolidighan dora - Eghizdin istimal
qilidighan Insulin (hazir tehi tetqiqat we muqimlinish basquchida) larning tetqiqatigha kozge korunerlik
tohpilerni qoshti. Hazirgha qeder u, 130 parchidin artuq ilmi maqalilerni xelghara tibbi dora tetqiqat
jornallarda we xelq'araliq tibbi dora tetqiqat yighinlarda ilan qildi. Shundaqla yene dora ilmigha ait
kitaplarning baplirini yizip chiqti. U tibbi dora tetqiqat saheside yene 2 patent hoquqige irishti.
Dr. Rishat Abbas Borhan nurghun qetim ministirlik we xelgharaliq pen-tetqiqat jemiyetlirining
teqdirleshliri we mukapatlashlirigha sazawer boldi. Bularning ichide 1996- yili Amerika Dolet Mudapie
Ministirligi (the U.S. Department of Defense) teripidin uninggha birilgen "Pen we Texnika Netije
Mukapati" (Science and Technology Achievement Award), 1996- yili Amerika Hawa Armiye Bash
Ishtabidin (the U.S. Department of Air Force) birilgen "Ppen-tetqiqat Netije Mukapati" (Scientific
Achievement Award) alahide kozge korunerliktur. bir parche maqalisi 1999-yili "Zeherlik maddilar ilmi
jemiyiti" (Society of Toxicology) teripidin "munewwer eser" bolup bahalan'ghan. 2001--yili xelghara
Diabetes kisili texnikiliq yighinida yene bir parche maqalisi "Eng yaxshi mezmunluq maqale" bolup
bahalan'ghan. 2009-yili Uning kokrek rak kiselliklirige qarshi dora tetqiqat netijisi "Pewqul'adde
ijadiliqqa ige netije" mukapatigha iriship bu sahediki tetqiqatqa qoshqan zor tohpisi alahide tilgha elinip
tonushturuldi. Undin bashqa yene 2009-yili, qan rak kiselliklirige qarshi dora tetqiqat netijisi bu sahege
qoshqan tetqiqat tohbisining alahide yuquri sewiyede bolghanlighi uchun "Yingi bir pellige yetkenlerni
itirap qilish" mukapatigha irishken.
PUBLICATION (Peer Reviewed Journals and Abstracts):
1. Abbas R, Leister C, Sonnichsen D. A clinical study to examine the potential effect of lansoprazole on the
pharmacokinetics of bosutinib when administered concomitantly to healthy subjects. Clinical Drug
Investigation: Volume 33, Issue 8 (2013), Page 589-595
2. Richat Abbas, Stephan Chalon, Cathie Leister, Myriam El Gaaloul, Daryl Sonnichsen. Evaluation of the
pharmacokinetics and safety of bosutinib in patients with chronic hepatic impairment and matched healthy
subjects. Cancer Chemother Pharmacol (2013) 71:123–132. DOI 10.1007/s00280-012-1987-7
3. Chow, L.W.-C., Xu, B., Gupta, S., Freyman, A., Zhao, Y., Abbas, R., Vo Van, M.-L., Bondarenko,
I. Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast
cancer. British Journal of Cancer: volume 108, issue 10, year 2013, pp. 1985 – 1993
(E-mail: [email protected])
4. Richat Abbas, PhD; Cathie Leister, MS; Myriam El Gaaloul, PharmD; Stephan Chalon, MD, PhD; and Daryl
Sonnichsen, PharmD. Ascending Single-Dose Study of the Safety Profile, Tolerability,and Pharmacokinetics
of Bosutinib Coadministered With Ketoconazole to Healthy Adult Subjects. Clinical Therapeutics/Volume
34, Number 9, September 2012, pp 2011 – 2019.el. doi: 10.1016/j.clinthera.2012.07.006. Epub 2012 Aug 9.
PMID: 22884766 [PubMed - indexed for MEDLINE]
5. Richat Abbas, Bruce A. Hug, Cathie Leister, Daryl Sonnichsen. A double-blind, randomized, multiple-dose,
parallel-group study to characterize the occurrence of diarrhea following two different dosing regimens of
neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor. Cancer Chemother Pharmacol. 2012
Jul;70(1):191-9. doi: 10.1007/s00280-012-1857-3. Epub 2012 Mar 15. PMID:22418773[PubMed - indexed
for MEDLINE]
6. Abbas R, Hug BA, Leister C, Gaaloul ME, Chalon S, Sonnichsen D. A phase I ascending single-dose study of
the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects. Cancer
Chemother Pharmacol (2012) 69:221–227.
7. Daud A, Krishnamurthi S, Saleh M, Gitlitz BJ, Borad MJ, Gold PJ, Chiorean EG, Springett GM, Abbas R,
Agarwal S, Bardy-Bouxin N, Hsyu PH, Leip E, Turnbull K, Zacharchuk C, Messersmith W. Phase 1 Study
of Bosutinib, a Src/Abl Tyrosine Kinase Inhibitor, Administered to Patients With Advanced Solid Tumors.
Clin Cancer Res. 2012 Feb 15;18(4):1092-100. doi: 10.1158/1078-0432.CCR-11-2378. Epub 2011 Dec 16.
8. Richat Abbas, Bruce A. Hug, Cathie Leister, Daryl Sonnichsen. A randomized, crossover, placebo- and
moxifloxacin-controlled study to evaluate the effects of bosutinib (SKI-606), a dual Src/Abl tyrosine kinase
inhibitor, on cardiac repolarization in healthy adult subjects. Int J Cancer. 2011 Nov 8. doi:
10.1002/ijc.27348.
9. Cortes JE, Kantarjian HM, Brümmendorf TH, Kim DW, Turkina AG, Shen ZX, Pasquini R, Khoury HJ, Arkin S, Volkert A, Besson N, Abbas R, Wang J, Leip E, Gambacorti-Passerini C. Safety and efficacy of bosutinib
(SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with
resistance or intolerance to imatinib. Blood. 2011 Oct 27;118(17):4567-4576.
10. Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D. Pharmacokinetics of oral neratinib during co-
administration of ketoconazole in healthy subjects. Br J Clin Pharmacol. 2011 Apr;71(4):522-7. doi: 10.1111/j.1365-2125.2010.03845.x. 11. Jorge E. Cortes, Hagop M. Kantarjian, Tim H. Brümmendorf, Dong-Wook Kim, Anna G. Turkina, Zhi-Xiang Shen, Ricardo Pasquini, H. Jean Khoury, Steven Arkin, Angela Volkert, Nadine Besson, Richat Abbas,
Junyuan Wang, Eric Leip, and Carlo Gambacorti-Passerini. Safety and efficacy of bosutinib (SKI-606) in
chronic phase Philadelphia chromosome–positive CML patients with resistance or intolerance to imatinib
Blood-2011-05-355594; published ahead of print August 24, 2011, doi:10.1182/Blood-2011-05-355594
12. Ramona F. Swaby, Zefei Jiang, Yan Sun, Khalil Zaman, Veronique Dieras, Charles Zacharchuk, Christine A. Powell, Richat Abbas, Mayuri Thakuria, Amy Freyman, and Kimberly L. Blackwell. A Phase I/II Study of
Neratinib (HKI-272) in Combination with Trastuzumab for the Treatment of Patients with Advanced Breast
Cancer; submission to the Journal of Clinical Oncology, 2011.
13. R. Abbas, B. Hug, C. Leister, J. Burns, D. Sonnichsen Effect of Ketoconazole on the Pharmacokinetics (PK)
of Bosutinib (SKI-606) in Healthy Subjects. J Clin Pharmacol. December 2011 vol. 51 no. 12 1721-1727.
14. Bruce Hug, Richat Abbas, Cathie Leister, Jaime Burns, Daryl Sonnichsen. A Single Dose, Crossover, Placebo-
and Moxifloxacin-Controlled Study to Assess the Effects of Neratinib (HKI-272) on Cardiac Repolarization
in Healthy Adult Subjects. Clinical Cancer Research. 16(15), 4016-4022, August 1, 2010.
15. Harold J. Burstein, Yan Sun, Luc Y. Dirix, Zefei Jiang, Robert Paridaens, Antoinette R. Tan, Ahmad Awada, Anantbhushan Ranade, Shunchang Jiao, Gary Schwartz, Richat Abbas, Christine Powell, Kathleen Turnbull,
Jennifer Vermette, Charles Zacharchuk, Rajendra Badwe. Neratinib, an Irreversible ErbB Receptor Tyrosine
Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer. Journal of Clinical Oncology,
Vol 28, No 8 (March 10), 2010: pp. 1301-1307
16. Kwok-K. Wong, Paula M. Fracasso, Ronald M. Bukowski, Thomas J. Lynch, Pamela N. Munster, Geoffrey I. Shapiro, Pasi A. Jänne, Joseph P. Eder, Michael J. Naughton, Matthew J. Ellis, Suzanne F. Jones, Tarek
Mekhail, Charles Zacharchuk, Jennifer Vermette, Richat Abbas, Susan Quinn, Christine Powell, and
Howard A. Burris. A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine
Kinase Inhibitor, in Patients with Solid Tumors. Clin Cancer Res 2009 15: 2552-2558.
17. Joseph Boni, Richat Abbas, Cathie Leister, Jaime Burns, Ronald Jordan, Mattew Hoffmann, William Demaio,
and Bruce Hug. Disposition of Desipramine, a Sentisive Cytochrome P450 2D6 Substrate, When
Coadministered with Intravenous Temsirolimus, Cancer Chemother Pharmacol (2009) 64:263-270.
(E-mail: [email protected])
18. Grant Sellar, John D Alvarez, Frank Loganzo, Richat Abbas, Fred Immermann, Maha Karnoub, Giora Z
Feuerstein, Michael E Burczynski, Christina M Coughlin. Opportunities posed by novel patient selection
biomarker approaches in oncology drug development: going beyond the cytotoxics. Biomarkers in Medicine,
April 2008, Vol. 2, No. 2, Pages 147-153.
19. Gunnar Folprecht, Josep Tabernero, Claus-Henning Köhne, Charles Zacharchuk, Luis Paz-Ares, Federico Rojo, Susan Quinn, Esther Casado, Ramon Salazar, Jordi Andreu, Richat Abbas, Chantal Lejeune, Irene Marimón,
Jordi Andreu, Ulrike Ubbelohde, Hernan Cortes-Funes, Jose Baselga. Phase I PK/PD study of EKB-569 - an
irreversible inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase - in combination with
irinotecan, 5-fluorouracil and leucovorin (FOLFIRI) in first-line treatment of patients with metastatic
colorectal cancer. Clinical Cancer Research 14, 215, January 1, 2008.
20. Laheru Dan; Croghan Gary; Bukowski Ronald; Rudek Michelle; Messersmith Wells; Erlichman Charles; Pelley Robert; Jimeno Antonio; Donehower Ross; Boni Joseph; Abbas Richat; Martins Patricia; Zacharchuk
Charles; Hidalgo Manuel. A phase I study of EKB-569 in combination with capecitabine in patients with
advanced colorectal cancer. Clinical cancer research: 2008;14(17):5602-9.
21. R Abbas, Y Hijazi, JP Tang, LM Renzetti, A Rames and H Welker. Effect of R411, a Dual 4/1-4/7
Integrin Antagonist Being Developed for Asthma, on the Activities of the Major Drug Metabolizing Enzymes After Oral Administration in Healthy Subjects. Clinical Pharmacolgy & Therapeutics, Vol. 75, No.2, p-79, 2004. 22. Richat Abbas, Scott Fettner, Myriam Riek, Sunita Bulsara, Michael Pantze, Marta Hamilton, Paul Frohna, and
Ashok Rakhit A drug-drug interaction study to evaluate the effect of rifampicin on the pharmacokinetics of the EGF receptor tyrosine kinase inhibitor, TarcevaTM, in healthy subjects. Proc Am Soc Clin Oncol 22: page 137, a-548, 2003 23. C. Kapitza, E. Arbit, R. Abbas, M. Goldberg, M. Hompesch, L. Heinemann, T. Heise, Oral Insulin: Proof of
concept in type 2 diabetic patients. Diabetes. 52-S.1. A37, 2003. 24. Ashok Rakhit, Scott Fettner, Stephen Davis, Richat Abbas, Flavio De Rosa, Ulrich Brennscheidt, Chis Twelves
and Jose Baselga. Lack of pharmacokinetic interaction between erlotinib, docetaxel and capecitabine in breast cancer patients. European Journal of Cancer Supplements; Vol. 1, No. 5, p-S115 Sept. 2003. 25. Ashok Rakhit, Scott Fettner, Myriam Riek, Stephen Davis, Marta Hamilton, Paul Frohna, Richat Abbas.
Clinical pharmacokinetics of erlotinib in healthy subjects. European Journal of Cancer Supplements; Vol. 1, No. 5, p-S168, Sept. 2003. 26. Zhongping John Lin, Richat Abbas , Lorraine M. Rusch and Linyee Shum - Development and Validation of a
Sensitive LC-MS/MS Method for the Determination of Cromolyn in Human Plasma, Journal of Chromatography B 788 (2003) 159-166 27. Richat Abbas, Andrea Leone-Bay, Rajesh Agawal, Shingai Majuru, Paul Rolan, Cyril Clarke, Colin Scott,
Arbit, Robert A. Baughman - Oral Insulin: Pharmacokinetics and Pharmacodynamics of Human Insulin Following Oral Administration of an Insulin/Delivery Agent Capsule in Healthy Volunteers. Diabetes. 2002, Volume 51, A48, S. 2. 28. Richat Abbas, Robert A. Baughman, S. De Bruyn2, Donald Sarubbi, and Ehud Arbit - Oral Cromolyn:
Pharmacokinetics of Cromolyn Sodium Delivered Orally in Healthy Volunteers. Allergy Vol. 57, S73, 338, 2002 29. Richat Abbas, Rajesh Agarwal, Terry Rivera-Schaub, Andrea Leone-Bay, Kiran Chaudhary, and Robert A.
Baughman - Evaluation of the Effect of Three Different Oral Heparin/SNAC Formulations on Pharmacokinetics (PK) of Heparin Following Oral Administration in Healthy Subjects. Pharm. Sci Vol. 4, No. 4, R621, 2002. 30. Richat Abbas, A.Chaouki Zerouala, and Robert A. Baughman. PHARMACOKINETICS (PK) AND
PHARMACODYNAMICS (PD) OF SNAD/HEPARIN IN RHESUS MONKEYS. “Drug Metabolism Review” Vol. 33, 400, 2001. 31. Richat Abbas, Alda Pombo-Gentile, and Robert A. Baughman. Absolute bioavailability of SNAD and
Pharmacokinetics of SNAD/heparin in rats. “Drug Metabolism Review” Vol. 33, 124, 2001. 32. Lorraine M. Rusch, Richat Abbas, Catherina M. O’Shaughnessy, Liangfu Chen, and Robert A. Baughman.
Interspecies Comparison of SNAC and SNAD IN VITRO PLASMA PROTEIN BINDING. “Drug Metabolism Review” Vol. 33, 233, 2001. 33. Catherina M. O’Shaughnessy, Lorraine M. Rusch, Richat Abbas, Liangfu Chen and Robert A. Baughman. IN
VITRO EVALUATION OF SNAC INTERACTION WITH HUMAN CYP450 ISOENZYMES. “Drug Metabolism Review” Vol. 33, 381, 2001. (E-mail: [email protected])
34. Richat Abbas, Gregory Osgood, Terry Rivera-Schaub, James C. Kisicki, and Robert A. Baughman. A Clinical
Drug-interaction Study to Evaluate Effect of Antacid Pre-treatment on the Absorption of Heparin and its Delivery Agent, SNAC, Following Oral Administration in Healthy Subjects. Pharm. Res. Vol. 21, No., pp. s. 2001. 35. Richat Abbas, Andrea Leone-Bay, Terry Rivera-Schaub, Shingai Majuru, James C. Kisicki, and Robert A.
Baughman. An Open-label, Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of SNAD, an Oral Heparin Delivery Agent, when Administered Orally as SNAD Tablets or Heparin/SNAD Tablets to Healthy Male Volunteers. Pharm. Res. Vol. 21, No., pp. s- 2001. 36. Abbas, R., Chow, C. P., Browder, N. J., Thacker, D., Bramer, S. L., Fu, C. H. J., Forbes, W., Odomi, M. and
Flockhart, D.A. In vitro Metabolism and Interaction of Cilostazol with Human Hepatic Cytochrome P450 Isoforms. Human & Experimental Toxicology. 19(3). March, 2000. 178-184. 37. Lash, L. H., Putt, D. A. Brashear, W. T., Abbas, R., Parker, J. C., and Fisher, J. W. Identification of S-(1,2-
Dichlorovinyl) glutathione in the blood of human volunteers exposure to trichloroethylene J. Toxicol Environ. Health 56: 1-21, 1999. 38. Gu, Z., Tata, P. Zhou, D., Abbas, R., Wu, J., Lewis, N. J., and Bramer, S. L. Sensitive and specific LC-MS/MS
method for the analysis of low levels of OPC-29030 and ten metabolites in human plasma and urine. Pharm. Sci. Suppl. Vol. 1, No. 1, s-189, 1998. 39. Abbas, R., Bramer, S. L., Cowart, D., Adeyemo, O. M., Kitani, M., Miyamoto, G., and Browder, N. J.
Interspecies Comparison of TOBORINONE Pharmacokinetics in Rats, Rabbits, Dogs, Monkeys, and Humans. Toxicological Sciences, vol. 42, No.1-S, p216, 1998. 40. Adeyemo, O.M., R. Abbas, D. Sibley, R. Mailman, R. Wilcox, T. Kikuchi, T. Hirose, and N. J. Browder, OPC-
14597: Unique pharmacology and receptor binding characterization studies on a novel antipsychotic agent, The Toxicologist, 42, No. 1215, p. 246, 1998. 41. Abbas, R., Flockhart, D. A., Thacker, D., Bramer, S. L., Cowart, D., and Browder, N. J. In vitro metabolism of
toborinone by human liver cytochrome P450 isoforms. Toxicology Letters, vol. 95, S1, p101, 1998. 42. Fisher, J.W., Mahle, D. and Abbas, R. A Human Physiologically Based Pharmacokinetic Model for
Trichloroethylene and its Metabolites, Trichloroacetic Acid and Free Trichloroethanol. Toxicol. Appl. Pharm. 152, 339-359, 1998. 43. Browder, N. J., Flockhart, D. A., Thacker, D., Bramer, S. L., Cowart, D., and Abbas, R. EFFECT OF
TOBORINONE ON HUMAN LIVER CYTOCHROME P450 ISOFORMS AND INTERACTION WITH THEOPHYLLINE. Toxicological Sciences, vol. 42, No.1-S, p91, 1998. 44. Fu, C. J., Abbas, R., Tata, P. N. V., Cowart, C., Bramer, S. L. AN HPLC METHOD FOR THE ANALYSIS OF
TOBORINONE (OPC-18790) AND FOUR METABOLITES IN HUMAN PLASMA. Toxicological Sciences, vol. 42, No.1-S, p219, 1998. 45. Abbas, R. Tata, P. Bramer, S. L. Li, Y. X. Heitkamp, J. and Velagaleti, P. A SENSITIVE AND SPECIFIC
CHIRAL HPLC-MS/MS METHOD FOR QUANTITATIVE ANALYSIS OF LOW LEVELS OF R(+) AND S(-) ENANTIOMERS OF OPC-41061 IN HUMAN SERUM. Pharm. Res. Vol. 14, No. 11, pp. s-360, 1997. 46. Abbas, R. Browder, N. J. Chow, P. Odomi, M. and Bramer, S. L. INTERSPECIES COMPARISON OF
CILOSTAZOL PHARMACOKINETICS IN MICE, RATS, DOGS, MONKEYS, AND HUMANS. Pharm. Res. Vol. 14, No. 11, pp. s-360, 1997. 47. Moghaddam, A. P., Abbas, R., Fisher, J. W, and Lipscomb, J. C. The role of mouse intestinal microflora in the
metabolism of Trichloroethylene, an In Vitro Study.Human and Experimental Toxicology. 16, 629-635. 1997. 48. Fu, C. J., Abbas, R. Tata, P. Chow, P. Browder, N. J. and Bramer, S. L. An HPLC method for the analysis of
toborinone and four metabolites in human liver microsomal incubation solutions. Pharm. Res. Vol. 14, No. 11, pp. s-566, 1997. 49. Abbas, R., Seckel, C. S., Kidney, J. K., and Fisher, J. W. PHARMACOKINETIC ANALYSIS OF
CHLORAL HYDRATE AND ITS METABOLISM IN B6C3F1 MICE. Drug Metabolism and Disposition. Vol. 24, No. 12 p 1340-1346. 1996. 50. Abbas, R., and Fisher, J. W. A physiologically based pharmacokinetic model for trichloroethylene and its
metabolites, chloral hydrate, trichloroacetate, dichloroacetate, trichloroethanol, and trichloroethanol
glucuronide in B6C3F1 mice. Toxicol. Appl. Pharm. 127, 15-30, 1997.
51. Abbas, R. and W. L. Hayton. A Physiologically Based Pharmacokinetic and Pharmacodynamic Model for
Paraoxon in Rainbow Trout. Toxicol. Appl. Pharmacol., 145, 192-201, 1997.
52. Abbas, R., Schultz, I. R., Doddapaneni, S. and Hayton, W. L. Toxicokinetics of Parathion and Paraoxon in
Rainbow Trout after Intravascular Administration and Water Exposure. Toxicol. Appl. Pharmacol. 136, 194-199, 1996. (E-mail: [email protected])
53. Abbas R., and Hayton W L. Gas Chromatographic Determination of Parathion and paraoxon in fish plasma and
tissues. Journal of Analytical Toxicology, Vol. 20, 151-154, 1996. 54. Moghaddam, A. P., Abbas, R., Fisher, J. W., Stavrou, S., and Lipscomb, J. C. Formation of dichloroacetic acid
by rat and mouse gut microflora, an in vitro study. Biochem. Biophys. Res. Comm. 228, 639-645, 1996.
55. Brashear. W. T., Bishop, C. T., and Abbas, R. Electrospray analysis of biological samples for trace amounts of
trichloroacetic acid, dichloroacetic acid and monochloroacetic acid. J. of Anal. Tox. 21, 330-334, 1997.
56. Abbas, R., Seckel, C. S. and Fisher, J. W.: Determination of kinetic rate constants for chloral hydrate,
trichloroethanol, trichloroacetate and dichloroacetate: a PBPK model approach. The Toxicologist, vol. 36, No. 1, 164, 1997. 57. Fisher, J. W , J. D. Pleil, MacMahon, K. L. and Abbas, R.: A Physiologically Based Pharmacokinetic Model for
inhalation of trichloroethylene in human volunteers. The Toxicologist, vol. 36, No. 1, 163, 1997. 58. Greenberg, M.S. Abbas, R. and Fisher, J. W: A Physiologically Based Pharmacokinetic Model for inhaled
trichloroethylene and its major metabolites in B6C3F1 mice. The Toxicologist, vol. 36, No. 1, 162, 1997. 59. Geiss, K. T., Young, R. S., Randall, G., Kidney, J. K. Channel, S. R. and Abbas, R.: Induction of Peroxisome
Proliferation-Associated genes after administration of Trichloroethylene to Mice. The Toxicologist, vol. 36, No. 1, 1185, 1997. 60. Bishop, C. T., Brashear, W. T., Pollard, D. L., and Abbas, R.: Analysis of Trichloroethylene in Biological
Samples. The Toxicologist, vol. 36, No. 1, 1630, 1997. 61. Zhang, H. M, Brashear, W. T., Buttler, G. T., Callaghan, P. Black, R. and Abbas, R. : An Electron Capture Gas
Chromatography Method for Analysis of Dichloroacetic Acid, Trichloroacetic Acid and Trichloroethanol in Biological Matrices. The Toxicologist, vol. 36, No. 1, 1631, 1997. 62. Lipscomb, J.C., Black, R.K., Janicki, T. J., Mahle D. A., Fisher, J. W. and Abbas, R.: Destruction of
Cytochrome P450 in Vitro by Trichloroethylene: Loss of CYP3A and CYP1A Activity. The Toxicologist, vol. 36, No. 1, 1610, 1997. 63. Moghaddam, A. P., Abbas, R., Fisher, J. W, Stavrou, S. and Lipscomb, J. C. Metabolism of Trichloroethylene
and Trichloroacetic Acid by Mouse Gut Microflora, an In Vitro Study. The Toxicologist, vol. 36, No. 1, 1610, 1997. 64. Abbas, R., Fisher, J. W. Black, R. K. and Garrity, B. L. A Physiologically Based Pharmacokinetic Model to
Describe Disposition of Chloral hydrate and Trichloroethanol in Mice. The International Toxicologist, 1995, 33-20. 65. Hayton, W L, Yu. Z., Abbas, R., Vick, A. and Doddapaneni, S. Pharmacokinetics of Acriflavine in Rainbow
Trout. The International Toxicologist, 1995, 89-16. 66. Abbas, R., Fisher, J. W., Black, R. K., Janicki, T. J. and Garrity, B. L. Disposition of Trichloroethylene and Its
Metabolites in B6C3F1 Mice after Oral Administration. Pharm. Res. Vol. 12, No. 9, pp. s-338. 1995. 67. Abbas, R. and Hayton, W. L., 1993. Paraoxon Tissue Distribution and AChE Inhibition in Rainbow Trout.
Pharm. Res. Vol. 10, No. 10, s-365. 68. Doddapaneni, S., Hayton, W. L., Schultz, I. R. and Abbas, R., 1993. Tissue Distribution and Metabolic
Disposition of Parathion in Rat. Pharm. Res. Vol. 10, No. 10, s-365. 69. Doddapaneni, S., Herzberg, U., Schultz, I.R. and Abbas, R. and Hayton, W.L., 1992. Parathion and Paraoxon
Pharmacokinetics and AChE Inhibition in Rat. Pharm. Res. Vol. 9, No.10,s 268. 70. Abbas, R., Schultz, I. R., Doddapaneni, S. and Hayton, W. L., 1992. Pharmacokinetics of Paraoxon in
Rainbow Trout. The Toxicologist, 12:1554.
CONFERENCE PRESENTATION:
71. Richat. Abbas, Bruce Hug, Cathie Leister, Daryl Sonnichsen. A Clinical Study to Assess Effect of Rifampin on
the Pharmacokinetics (PK) of Neratinib (HKI-272), a pan-ErbB Receptor Tyrosine Kinase Inhibitor, when Administered Concomitantly in Healthy Subjects. Presented at the Annual Meeting of American Society of Clinical Pharmacology and Therapeutics, March 12 – 17, 2012, National Harbor, MD (Clinical Pharmamacology and Therapeutics, Vol. 91, S. 1, March 2012) 72. Poe-Hirr Hsyu, Diane Mould, Richat Abbas, Stuart Pearce, Michael Amantea. A Population Pharmacokinetic Model of
Bosutinib, Presented at the AACR-NCI-EORTC, International Conference on Molecular Targets and Cancer Therapeutics, Nov. 12 -1 16, 2011, San Francisco, CA 73. R. Abbas, B. Hug, C. Leister, J. Burns, and D. Sonnichsen. A Clinical Study to Evaluate the Effect of Multiple Doses
of Lansoprazole on the Pharmacokinetics of Bosutinib (SKI-606), a Dual Inhibitor of Src and Abl Tyrosine Kinases, When Administered Concomitantly to Healthy Subjects. American Association of Pharmaceutical Scientists (AAPS) Annual Meeting, Oct. 23-27, 2011. Washington, DC (E-mail: [email protected])
74. R. Abbas, C. Leister, B. Hug, and D. Sonnichsen. Effect of Multiple Doses of Neratinib on the Pharmacokinetics of
Single-dose Digoxin in Healthy Subjects. American Association of Pharmaceutical Scientists (AAPS). Annual Meeting, Oct. 23-27, 2011. Washington, DC 75. Abbas R, Chalon S, Leister C, El Gaaloul M, Sonnichsen D. A Clinical Study to Assess Pharmacokinetics and Safety of
Neratinib in Subjects with Chronic Hepatic Impairment and Matched Healthy Subjects. 2011 European Multidisciplinary Cancer Congress (ECCO-ESMO), September 23-27, 2011. Stockholm, Sweden, 76. L. Chow,,* S. Gupta, D. L. Hershman, R. Epstein, I. Bondarenko, M-L. Vo Van, A. Freyman, Y. Zhao, R. Abbas, A.
Awada. Efficacy and Safety of Neratinib (HKI-272) in Combination With Paclitaxel in Her2+ Metastatic Breast Cancer. Poster Presented at the 33rd Annual San Antonio Breast Cancer Symposium, December 8-12, 2010, San Antonio, Texas. 77. Elzbieta Staroslawska, Luc Dirix, Thehang Luu, Véronique Diéras, Luis Manso, Binghe Xu, Junlan Yang, Richat Abbas,
Andrew Strahs, Marie-Louise Vo Van, Anna Berkenblit, Valérie Agrapart, Christine Powell, Ahmad Awada. Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2+ metastatic breast cancer pretreated with anti-HER2 therapy. Poster Presented at the 33rd Annual San Antonio Breast Cancer Symposium, December 8-12, 2010, San Antonio, Texas. 78. Abbas-Borhan R, Hug BA, Leister C, Burns J, Sonnichsen D. A clinical study to characterize the occurrence of mild-to-
moderate diarrhea after administration of neratinib either once daily or twice daily for 14 days. Abstract #454 available at http://www.ecco-org.eu/Conferences-and-Events/EORTC-NCI-AACR-2010/Abstracts-online/page.aspx/2528. Poster 195 presented at the 22nd EORTC-NCI-AACR symposium on Molecular Targets and Cancer Therapeutics. Berlin, Germany, November 16-19, 2010. 79. Abbas-Borhan R, Hug BA, Leister C, Burns J, Sonnichsen D. A single-dose study to evaluate the relative bioavailability
and pharmacokinetics of three new tablet formulations, an oral solution, and a reference capsule of bosutinib in healthy subjects. Abstract M1465 available at http://abstracts.aapspharmaceutica.com/pswc2010/Itinerary/login.asp. Poster presented at the International Pharmaceutical Federation (FIP) Pharmaceutical Sciences World Congress (PSWC) in association with the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting in New Orleans, Louisiana, USA, November 14-18, 2010. 80. Abbas-Borhan R, Hug BA, Leister C, Burns J, Sonnichsen D. Assessment of bioequivalence of phase III and commercial
formulations of bosutinib tablets in healthy volunteers. Abstract M1466 available at http://abstracts.aapspharmaceutica.com/pswc2010/Itinerary/login.asp. Poster presented at the International Pharmaceutical Federation (FIP) Pharmaceutical Sciences World Congress (PSWC) in association with the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting in New Orleans, Louisiana, USA, November 14-18, 2010. 81. Abbas-Borhan R, Chalon S, Leister C, El Gaaloul M, Sonnichsen D. Evaluation of pharmacokinetics (PK) and safety of
bosutinib in patients with chronic hepatic impairment (HI) and matched healthy subjects. Abstract #401 available at http://www.ecco-org.eu/Conferences-and-Events/EORTC-NCI-AACR-2010/Abstracts-online/page.aspx/2528. Presented at the 22nd EORTC-NCI-AACR symposium on Molecular Targets and Cancer Therapeutics. Berlin, Germany, November 16-19, 2010. 82. Richat Abbas, PhD; Poe-Hirr Hsyu, PhD; Joseph Boni, PhD. Pharmacokinetic (PK) assessment of bosutinib (SKI-606)
administered orally to patients with advanced solid tumors in a phase 1 study. Presented at the 22nd EORTC-NCI-AACR symposium on Molecular Targets and Cancer Therapeutics. Berlin, Germany, November 16-19, 2010. 83. Richat Abbas, PhD; Cathie Leister, MS; Christina Coughlin, MD, PhD; Daryl Sonnichsen, PharmD. Evaluation of
Neratinib (HKI-272) and Paclitaxel Pharmacokinetics (PK) in Asian and Caucasian Patients with ErbB2+ Breast Cancer: A Phase 1/2 Study of Neratinib in Combination with Paclitaxel. 35th Congress of the European Society for Medical Oncology. Milan, Italy. October 8 - 12, 2010. 84. Richat Abbas-Borhan, PhD; Inder Chaudhary, PhD; Joel Kantrowitz, PhD, Bruce A. Hug, MD, PhD; Cathie Leister, MS;
Jaime Burns, BS; Daryl Sonnichsen, PharmD. An Open-Label Study to Assess the Mass Balance and Metabolic Disposition of an Orally Administered Single Dose of 14C-Labeled Neratinib, an Irreversible pan-ErbB inhibitor, in Healthy Subjects. Presentation at the 9th International ISSX (International Society for the Study of Xenobiotics) Meeting (www.issx2010.org) in Istanbul, Turkey September 4 - 8, 2010. 85. Richat Abbas-Borhan, PhD; Inder Chaudhary, PhD; Bruce A. Hug, MD, PhD; Cathie Leister, MS; Jaime Burns, BS;
Sarvesh Vashishtha, PhD; John C.L. Erve, PhD; Daryl Sonnichsen, PharmD. Mass Balance, Metabolic Disposition, Metabolite Characterization, and Pharmacokinetics of Oral 14C-Labeled Bosutinib in Healthy Subjects. Presentation at the 9th International ISSX (International Society for the Study of Xenobiotics) Meeting (www.issx2010.org) in Istanbul, Turkey September 4 - 8, 2010. 86. Richat Abbas, Bruce A. Hug, Cathie Leister, Jaime Burns, and Daryl Sonnichsen. A Single Dose, Crossover, Placebo-
and Moxifloxacin-Controlled Study to Assess the Effects of Bosutinib (SKI-606) on Cardiac Repolarization in Healthy Adult Subjects. Presented at the Annual Meeting of the European Hemotogy Assciation, June 9-13. 2010, Barcelona, Spain. 87. R. Abbas, J. Boni, B. Hug, C. Leister, J. Burns, D. Sonnichsen. Evaluation of the Effect of Rifampin on the
Pharmacokinetics (PK) of Bosutinib (SKI-606), a Dual Inhibitor of Src and Abl Tyrosine Kinases, When Administered Concomitantly to Healthy Subjects. Presented at the Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, March 17-20, 2010, Atlanta, GA 88. R. Abbas, B. Hug, C. Leister, J. Burns, D. Sonnichsen. Assessment of the Effect of a High-Fat Meal on the Relative
Bioavailability and Pharmacokinetics (PK) of Bosutinib (SKI-606), a Dual Inhibitor of Src and Abl Tyrosine Kinases, in Healthy Subjects. Presented at the Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, March 17-20, 2010, Atlanta, GA 89. R. Abbas, B. Hug, C. Leister, J. Burns, D. Sonnichsen. Ascending Single-Dose Study of Safety, Tolerability, and
Pharmacokinetics of Bosutinib (SKI-606) in Healthy Subjects. Presented at the AACR-EORTC-NCI Meeting, November 15-19, 2009, Boston, MA 90. R. Abbas, B. Hug, C. Leister, J. Burns, D. Sonnichsen. Single-Ascending-Dose Study of Safety, Tolerability, and
Pharmacokinetics of Neratinib (HKI-272) in Healthy Subjects. Presented at the Annual Meeting of the American Association of Pharmaceutical Scientists, Nov. 08 - 12, 2009, Los Angeles, CA. AAPS Journal. 2009; 11(S2). 91. R. Abbas, C. Leister, R. Epstein, C. Coughlin, and D. Sonnichsen. Neratinib and Paclitaxel Pharmacokinetics in the
Chinese Patient Population in the Phase 1/2 Study of Neratinib in Combination with Paclitaxel in Patients with Solid Tumors and ErbB2+ Breast Cancer. Presented at the Annual Meeting of the Chinese Society of Clinical Oncology, October 14-18, 2009, Xiamen, China 92. M. El Gaaloul, R. Abbas, B. Hug, C. Leister, S. Chalon,1 D. Sonnichsen. Ascending single-dose study of the safety,
tolerability, and pharmacokinetics of bosutinib administered orally with multiple doses of ketoconazole to healthy adult subjects. 34h Congress of the European Society for Medical Oncology. Berlin, Germany, September 20-24, 2009. Eur J. Cancer Suppl. 2009. &. Abstract P-1239. 93. R. Abbas, B. Hug, C. Leister, J. Burns, D. Sonnichsen. A Drug Interaction Study to Evaluate the Effect of Ketoconazole
on the Pharmacokinetics (PK) of Neratinib in Healthy Subjects. Presented at the Annual Meeting of American Society of Clinical Pharmacology and Therapeutics, March 18 – 22, 2009, National Harbor, MD 94. R. Abbas, B. Hug, C. Leister, J. Burns, D. Sonnichsen Effect of Ketoconazole on the Pharmacokinetics (PK) of Bosutinib
(SKI-606) in Healthy Subjects. Presented at the Annual Meeting of American Society of Clinical Pharmacology and Therapeutics, March 18 – 22, 2009, National Harbor, MD 95. L. Chow, Z. Jiang, R. Epstein, I. Bondarenko, A. Awada, C. Coughlin, E. Gauthier, Y. Zhao, R. Abbas, D. Hershman.
Safety and Efficacy of Neratinib (HKI-272) in Combination With Paclitaxel in Patients With Solid Tumors. Journal of Clinical Oncology, 2009 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 27, No 15S (May 20 Supplement), 2009: 3557. 96. R. Swaby; K. Blackwell; Z. Jiang; Y. Sun; V. Dieras K. Zaman; C. Zacharchuk; C. Powell; R. Abbas; M. Thakuria.
Neratinib in Combination With Trastuzumab for the Treatment of Advanced Breast Cancer: A Phase 1/2 Study. Journal of Clinical Oncology, 2009 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 27, No 15S (May 20 Supplement), 2009: 1004. 97. A. Daud, S. Krishnamurthi, B. Hewes, C. Zacharchuk, R. Abbas, P. Martins, E. Dowling, A. Volkert, E. Martin, W.
Messersmith. Bosutinib, a Dual Src/Abl Tyrosine Kinase Inhibitor: Preliminary Results from a Phase 1 Study in Patients With Advanced Malignant Solid Tumors. Presented at the 43rd American Society of Clinical Oncology Annual Meeting June 1-5, 2007. Chicago, Illinois. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007. 98. C. Gambacorti-Passerini, T.H. Brümmendorf, H. Kantarjian, M. Baccarani, D. Liu, T. Fisher, B. Hewes, A.D.G. Volkert, R.
Abbas, J. Cortes. Bosutinib Exhibits Clinical Activity in Patients with Philadelphia Chromosome Positive CML or ALL
Patients who Failed Imatinib. Presented at the 43rd American Society of Clinical Oncology Annual Meeting June 1-5, 2007.
Chicago, Illinois. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20
Supplement), 2007: 7006
99. T.H. Brümmendorf, J. Cortes, H. Kantarjian, G. Martinelli, D. Liu, T. Fisher, B. Hewes, A.D.G. Volkert, R. Abbas, C.
Gambacorti-Passerini. SKI-606 exhibits clinical activity in patients with Philadelphia chromosome positive CML or ALL who failed imatinib. Presented at 2007 Annual Meeting of European Society of Hematology, 7-10 June 2007, Vienna, Austria. 100. J. Cortes, H. Kantarjian, M. Baccarani, T.H. Brümmendorf, D. Liu, G. Ossenkoppele, A.D.G. Volkert, BA, B. Hewes, L. Moore, R. Abbas, C. Zacharchuk, and C. Gambacorti-Passerini. A Phase 1/2 Study of SKI-606, a Dual
Inhibitor of Src and Abl Kinases, in Adult Patients with Philadelphia Chromosome Positive (Ph+) Chronic
Myelogenous Leukemia (CML) or Acute Lymphocytic Leukemia (ALL) Relapsed, Refractory or Intolerant of
Imatinib (ALL). Presented at The American Society of Hematology, 48th Annual Meeting and Exposition, Dec. 9-12,
2006, Orlando, FL. Blood (ASH Annual Meeting Abstracts) 2006. , 108: Abstract 168.
101. K. K. Wong, P. M. Fracasso, R. M. Bukowski, P. N. Munster, T. Lynch, R. Abbas, S. E. Quinn, C. Zacharchuk, H. Burris.
HKI-272, an irreversible pan erbB receptor tyrosine kinase inhibitor: Preliminary phase 1 results in patients with solid tumors. Journal of Clinical Oncology, (2006 ASCO Annual Meeting Proceedings) Part I. Vol 24, No. 18S (06-20 S.), 2006: 3018 102. G. Folprecht, J. Tabernero, L. Paz-Ares, J. Baselga, H. Cortes-Funes, E. Casado, F. Rojo, J. Vauthier, Richat Abbas, C.
Zacharchuk, C. Koehne. The irreversible EGFR tyrosine kinase inhibitor EKB-569 in combination with 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) in patients with advanced colorectal cancer (ACC): A phase I/IIa pharmacokinetic and serial skin and tumor pharmacodynamic study. 29th European Society for Medical Oncology (ESMO) Congress. Oct. 29 – Nov. 2, 2004, Vienna, Austria. 103. R. Abbas, J. Boni, C. Leister, K. Saluti, S. Quinn, C. Zacharchuk. Evaluation of Pharmacokinetic Interactions Between
EKB-569, an Irreversible Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinase, and Gemcitabine in Patients With Advanced Pancreatic Cancer. 2004 AAPS Annual Meeting and Exposition, November 7-11, 2004, Baltimore, Maryland (E-mail: [email protected])
104. R Abbas, Y Hijazi, JP Tang, LM Renzetti, A Rames and H Welker. Effect of R411, a Dual 4/1-4/7 Integrin
Antagonist Being Developed for Asthma, on the Activities of the Major Drug Metabolizing Enzymes After Oral Administration in Healthy Subjects Presented at the 2004 Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, March 24-27, 2004, Maimi Beach, FL 105. R Abbas, Y Hijazi, JP Tang, LM Renzetti, A Rames and H Welker. Safety, Tolerability, and Pharmacokinetics of R411, a
Dual 4/1-4/7 Integrin Antagonist, after Oral Administration of Single-Ascending Doses in Healthy Male Subjects. Presented at the 2004 Annual Meeting of the American Academy of Allergy, Asthma and Immunology, March 19 - 23, 2004, San Francisco, CA 106. R. Abbas, Y. Hijazi, J. P. Tang, L. M. Renzetti, A. Rames and H. Welker. Safety, Tolerability and Pharmacokinetics of
R411, a Dual 4/1 and 4/7 Integrin Antagonist after Multiple-ascending Doses in Healthy Subjects. Preseneted at the 2004 International Conference of the American Thoracic Society. May 21-26, 2004, Orlando, FL 107. Richat Abbas, Scott Fettner, Myriam Riek, Sunita Bulsara, Michael Pantze, Marta Hamilton, Paul Frohna, and Ashok
Rakhit A drug-drug interaction study to evaluate the effect of rifampicin on the pharmacokinetics of the EGF receptor tyrosine kinase inhibitor, TarcevaTM, in healthy subjects. American Society of Clinical Oncology, May 31 – June 3, 2003 Chicago, IL 108. C. Kapitza, E. Arbit, R. Abbas, M. Goldberg, M. Hompesch, L. Heinemann, T. Heise, Oral Insulin: Proof of concept in
type 2 diabetic patients. 18th International Diabetes Feration Congress, Aug. 24-29, 2003, Paris, France. 109. Richat Abbas, Scott Fettner, Myriam Riek, Steve Davis, Marta Hamilton, Paul Frohna, and Ashok Rakhit. Effect of
ketoconazole on the pharmacokinetics of erlotinib (TARCEVATM) in healthy adult male subjects. European Association of Clinical Pharmacology and Therapeutics (EACPT), June 24-28, 2003. Istanbul, Turkey 110. Ashok Rakhit, Scott Fettner, Stephen Davis, Richat Abbas, Flavio De Rosa, Ulrich Brennscheidt, Chis Twelves and Jose
Baselga. Lack of pharmacokinetic interaction between erlotinib, docetaxel and capecitabine in breast cancer patients.
Presented at the 12th annual Meeting of the Federation of European Cancer Society (ECCO-12), Sept. 21-25, 2003,
Copenhagen, Denmark
111. Ashok Rakhit, Scott Fettner, Myriam Riek, Stephen Davis, Marta Hamilton, Paul Frohna, Richat Abbas. Clinical
pharmacokinetics of erlotinib in healthy subjects. Presented at the 12th annual Meeting of the Federation of European Cancer Society (ECCO-12), Sept. 21-25, 2003, Copenhagen, Denmark. 112. Ehud Arbit MD, Richat Abbas PhD, Steve Dinh PhD and Michael Goldberg MD. The potential clinical implications of the
pharmacokinetic profiles of insulin administered by alternate routes. Presented at the 2002 Diabetes Technologies Annual Meeting, Nov. 2002, Atlanta, GA 113. Richat Abbas, Andrea Leone-Bay, Rajesh Agawal, Shingai Majuru, Paul Rolan, Cyril Clarke, Colin Scott,Ehud, Arbit,
Robert A. Baughman - Oral Insulin: Pharmacokinetics and Pharmacodynamics of Human Insulin Following Oral Administration of an Insulin/Delivery Agent Capsule in Healthy Volunteers – Presentation at the 62nd Annual Meeting American Diabetes Assciation, June 14-16, 2002, San Francisco, CA 114. Richat Abbas, Robert A. Baughman, S. De Bruyn, Donald Sarubbi, and Ehud Arbit - Oral Cromolyn: Pharmacokinetics of
Cromolyn Sodium Delivered Orally in Healthy Volunteers - Presentation at the the XXI Congress of the European Academy of Allergology and Clinical Immunology, 1-5 June 2002, Naples, Italy. 115. Richat Abbas, Rajesh Agarwal, Terry Rivera-Schaub, Andrea Leone-Bay, Kiran Chaudhary, and Robert A. Baughman -
Evaluation of the Effect of Three Different Oral Heparin/SNAC Formulations on Pharmacokinetics (PK) of Heparin Following Oral Administration in Healthy Subjects. Presented at the Annual Meeting of the American Association of Pharmaceutical Scientists. Nov. 10-14, 2002, Toronto, Canada 116. Richat Abbas, Robert A. Baughman, D. de Vries, Steve Dinh and, Ehud Arbit - Pharmacokinetics of Human Insulin
Delivered Orally in Healthy Volunteers – Presented at the Diabetes Technologies Meeting, (This was accepted as a best abstract and presented at Diabetes Technologies Meeting). Nov. 2-3, 2001, San Francisco. 117. Richat Abbas, A.Chaouki Zerouala, and Robert A. Baughman. PHARMACOKINETICS (PK) AND
PHARMACODYNAMICS (PD) OF SNAD/HEPARIN IN RHESUS MONKEYS. Presented at the 6th ISSX Annual Meeting, October 7-11, 2001, Munich, Germany 118. Richat Abbas, Alda Pombo-Gentile, and Robert A. Baughman. Absolute bioavailability of SNAD and Pharmacokinetics
of SNAD/heparin in rats. Presented at the 6th ISSX Annual Meeting, October 7-11, 2001, Munich, Germany. 119. Richat Abbas, Gregory Osgood, Terry Rivera-Schaub, James C. Kisicki, and Robert A. Baughman. A Clinical Drug-
interaction Study to Evaluate Effect of Antacid Pre-treatment on the Absorption of Heparin and its Delivery Agent, SNAC, Following Oral Administration in Healthy Subjects. Presented at the Annual Meeting of the American Association of Pharmaceutical Scientists. Oct. 2001, Denver, CO. 120. Richat Abbas, Andrea Leone-Bay, Terry Rivera-Schaub, Shingai Majuru, James C. Kisicki, and Robert A. Baughman. An
Open-label, Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of SNAD, an Oral Heparin Delivery Agent, when Administered Orally as SNAD Tablets or Heparin/SNAD Tablets to Healthy Male Volunteers. Presented at the Annual Meeting of the American Association of Pharmaceutical Scientists. Oct. 2001, Denver, CO. 121. Richat Abbas, Theresa Rivera-Schaub, Igor Rubets, Rajesh Agarwal and Robert A. Baughman. Clinical Pharmacokinetics
and Absolute Bioavailability of the Oral Delivery Agent SNAC when Dosed Orally as SNAC/Heparin to Healthy Volunteers. Presented at the Pharmaceutical Congress of Americas, March 24-29, 2001, Orlando FL. 122. Andrea Leone-Bay, Theresa Rivera-Schaub, Shingai Majuru, Richat Abbas, James Kisicki, and Robert A. Baughman.
PHASE I STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF AN ORAL HEPARIN TABLET. Presented at the American Society of Hematology 2001 Annual Meeting. December 7 - 11, 2001, Orlando, FL. (E-mail: [email protected])
123. Gu, Z., Tata, P. Zhou, D., Abbas, R., Wu, J., Lewis, N. J., and Bramer, S. L. A sensitive and specific LC-MS/MS method
for the analysis of low levels of OPC-29030 and ten metabolites in human plasma and urine. Presented at the Annual Meeting of the American Association of Pharmaceutical Scientists. Nov. 15-19. 1998, San Francisco, CA. 124. Abbas, R., Bramer, S. L., Cowart, D., Adeyemo, O. M., Kitani, M., Miyamoto, G., and Browder, N. J. Interspecies
Comparison of TOBORINONE Pharmacokinetics in Rats, Rabbits, Dogs, Monkeys, and Humans. Presented at the 37th Annual Meeting of the Society of Toxicology, March 1-5, 1998, Seattle, WA. 125. Abbas, R., Flockhart, D. A., Thacker, D., Bramer, S. L., Cowart, D., and Browder, N. J. In vitro metabolism of toborinone
by human liver cytochrome P450 isoforms. Presented at the 37th Annual Meeting of the Society of Toxicology, March 1-5, 1998, Seattle, WA. 126. Abbas, R. Tata, P. Bramer, S. L. Li, Y. X. Heitkamp, J. and Velagaleti, P. A LC-MS/MS METHOD FOR
QUANTITATIVE ANALYSIS OF LOW LEVELS OF R(+) AND S(-) ENANTIOMERS OF OPC-41061 IN HUMAN SERUM. Presented at the 6th European International Society for the Study of Xenobiotics Meeting, June 30-July 3, 1997, Gothenburg, Sweden. 127. Abbas, R. Tata, P. Bramer, S. L. Li, Y. X. Heitkamp, J. and Velagaleti, P. A SENSITIVE AND SPECIFIC CHIRAL
HPLC-MS/MS METHOD FOR QUANTITATIVE ANALYSIS OF LOW LEVELS OF R(+) AND S(-) ENANTIOMERS OF OPC-41061 IN HUMAN SERUM. Presented at the 12TH Annual Meeting of American Association of Pharmaceutical Scientists, Nov. 2-6, 1997. Boston. 128. Abbas, R. Browder, N. J. Chow, P. Odomi, M. and Bramer, S. L. INTERSPECIES COMPARISON OF CILOSTAZOL
PHARMACOKINETICS IN MICE, RATS, DOGS, MONKEYS, AND HUMANS. Presented at the 12TH Annual Meeting of American Association of Pharmaceutical Scientists, Nov. 2-6, 1997. Boston. 129. Abbas, R., Seckel, C. S. and Fisher, J. W.: Determination of kinetic rate constants for chloral hydrate, trichloroethanol,
trichloroacetate and dichloroacetate: a PBPK model approach. Presented at the 36th Annual Meeting of the Society of Toxicology, March 9-13, 1997, Cincinnati, OH. 130. R. Abbas, J. W. Fisher, R. K. Black, T. J. Janicki, and , K. MacMahan. Development of A Physiologically Based
Pharmacokinetic (PBPK) Model for Tricholoroethylene and its Metabolites B6C3F1 Mice. Presented at the 35th Annual Meeting of the Society of Toxicology, March 10-14, 1996, Anaheim, CA. 131. Abbas, R., Fisher, J. W. Black, R. K. and Garrity, B. L. A Physiologically Based Pharmacokinetic Model to Describe
Disposition of Chloral hydrate and Trichloroethanol in Mice. Presented at the International Congress of Toxicology – VII, July 2-6, 1995, Seattle, WA. 132. Abbas, R., Fisher, J. W., Black, R. K., Janicki, T. J. and Garrity, B. L. Disposition of Trichloroethylene and Its
Metabolites in B6C3F1 Mice after Oral Administration. Presented at the 10TH Annual Meeting of American Association of Pharmaceutical Scientists, Nov. 5-9, 1995. Miami, FL. 133. Abbas, R. and Hayton, W. L., In vivo Acetylcholinesterase Inhibition in Rainbow Trout after Water Exposure to Paraoxon.
Presented at the 25th Annual Pharmaceutics Graduate Student Research Meeting, 1993, West Lafayette, Indiana. 134. Abbas, R. and Hayton, W. L., Paraoxon Tissue Distribution and AChE Inhibition in Rainbow Trout. Presented at the 8TH
Annual Meeting of American Association of Pharmaceutical Scientists, Nov. 14-18, 1993, Lake Vuena Vista, FL. 135. Abbas, R., Schultz, I. R., Doddapaneni, S. and Hayton, W. L., 1992. Pharmacokinetics of Paraoxon in Rainbow Trout.
Presented at the 31st Annual Meeting of the Society of Toxicology, Feb. 23-28, 1992, Seattle, WA. PATENT:
136. Abbas, Richat, et al. “Oral insulin therapy”. United States Patent – 20030198666, U.S. Current Class: 424/452; 424/465;
514/3. U.S. Class at Publication: 424/452; 514/3; 424/465. International Class: A61K 038/28; A61K 009/48; A61K 009/20 137. Abbas, Richat, et al. “Formulations for Oral administration of Cromolyn Sodium” US Patenet No. 02789934.3-2123 –
Book Chapter and Proceeding:
138. Creech, J.R., R.K. Black, B.L. Garrity, R.J. Williams, J.N. McDougal, G.W. Jepson, R. Abbas, L. Dong, and A. Vinegar:
Inhalation Uptake and Metabolism of Iodohalogenated Compounds, CF3I, C6F13I, and C3F7I. AL/OE-TR-1995-0089 139. Analysis of Biological Materials and Xenobiotics – Enviromental Chemistry, Boca Raton, CRC Press LLC 2000

Source: http://akademiye.org/en/wp-content/uploads/2013/05/Biography-Publications-of-Rishat-Abbas-Borhan-Aug-2013.pdf